Alkermes plc found using ticker (ALKS) now have 12 analysts in total covering the stock. The consensus rating is ‘Hold’. The target price ranges between 39 and 22 with the average target price sitting at 28.83. Now with the previous closing price of 21.77 this would indicate that there is a potential upside of 32.4%. The 50 day moving average now sits at 22.38 and the 200 day moving average is 27.77. The company has a market cap of $3,495m. Company Website: http://www.alkermes.com
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company’s marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.